As bluebird plans its big split, rare disease head Andrew Obenshain recruits Ironwood vet as CFO
As Nick Leschly counts down his final month as chief bluebird — before taking on the new role of 2seventy CEO — he has unveiled a key hire and a couple of updates.
The planned spinout, which is now set to take place in mid-October, will split the current bluebird into two companies, keeping the rare disease and gene therapy pipeline under the original bluebird moniker while Leschly steers the ship at oncology-focused newco 2seventy. Following “an intense period” of internal prep work, it’s time to share plans with outsiders, he said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
